Objective: The purpose of the present study was to establish whether pump prime aprotinin could influence soluble adhesion molecules in patients undergoing elective coronary artery bypass surgery.
Design: Thirty patients admitted for first-time elective coronary artery bypass surgery were randomized into control or aprotinin groups. Patients in the aprotinin group received 280 mg of aprotinin in the pump prime. Plasma levels of soluble adhesion molecules were analyzed perioperatively.
Results: There were no significant changes in plasma sE-selectin after the operation in either group. Plasma sP-selectin increased significantly up to 20 h after reperfusion to the myocardium. Plasma sICAM-1 decreased in the early stage after cardiopulmonary bypass (CPB), then recovered at 4 h after reperfusion and a significant increase in sICAM-1 was observed 20 h later. There were no significant differences between the groups in postoperative changes in sP-selectin (p = 0.21) and sICAM-1 (p = 0.91).
Conclusion: Pump prime aprotinin did not influence plasma levels of E-selectin, P-selectin and ICAM-1 in the present patients. The present results do not support the concept of an anti-inflammatory effect of pump prime aprotinin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/140174302762659067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
3D-Printed Electrohydrodynamic Pump and Development of Anti-Swelling Organohydrogel for Soft Robotics.
Adv Mater
January 2025
School of Materials Science and Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore, 639798, Singapore.
Article Synopsis
- The study showcases improvements in electrohydrodynamic (EHD) pumps alongside a new 3D-printable organohydrogel designed for soft robotics.
- Using advanced digital light processing (DLP) technology, the researchers created a manifold pump array that can generate 90.2 kPa of pressure and deliver a flow rate of 800 mL per minute, far exceeding the capabilities of traditional EHD systems.
- The novel organohydrogel developed has a low swelling ratio, high stretchability, and durability under stress, making it ideal for dynamic applications in soft robotics, bioengineering, and vertical farming.
Association of current Schistosoma mansoni, Schistosoma japonicum, and Schistosoma mekongi infection status and intensity with periportal fibrosis: a systematic review and meta-analysis.
Lancet Glob Health
January 2025
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address:
Background: Periportal fibrosis is a severe morbidity caused by both current and past exposure to intestinal schistosomes. We aimed to assess the association between current infection status and intensity of Schistosoma mansoni, Schistosoma japonicum, or Schistosoma mekongi with periportal fibrosis.
Methods: In this systematic review and meta-analysis, we searched the Cochrane Central Register of Controlled Trials, Embase, Global Health, Global Index Medicus, and MEDLINE from database inception to June 18, 2024.
Recapitulation of physiologic and pathophysiologic pulsatile CSF flow in purpose-built high-throughput hydrocephalus bioreactors.
Fluids Barriers CNS
December 2024
Department of Chemical Engineering and Materials Science, Wayne State University, 6135 Woodward Avenue, Rm 1413, Detroit, MI, 48202, USA.
Background: Hydrocephalus, an accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain, is often treated via a shunt system to divert the excess CSF to a different compartment; if left untreated, it can lead to serious complications and permanent brain damage. It is estimated that one in every 500 people are born with hydrocephalus. Despite more than 60 years of concerted efforts, shunts still have the highest failure rate of any neurological device requiring follow-up shunt revision surgeries and contributing to the $2 billion cost of hydrocephalus care in the US alone.
View Article and Find Full Text PDFEbola disease: bridging scientific discoveries and clinical application.
Lancet Infect Dis
December 2024
Pandemic Sciences Institute, Oxford, UK.
The west Africa Ebola disease epidemic (2014-16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure in many ways-a slow, cumbersome, and disjointed effort by a global architecture that was not fit for purpose for a rapidly spreading outbreak. In the most affected countries, health-care workers and other responders felt helpless-dealing with an overwhelming number of patients but with few, if any, tools at their disposal to provide high-quality care.
View Article and Find Full Text PDFEmbedding treatment in stronger care systems.
Lancet Infect Dis
December 2024
Pandemic Sciences Institute, Oxford, UK.
A key lesson from the west Africa (2014-16) Ebola disease epidemic was that outbreak responses fail when they respond to patients through a narrow clinical lens without considering the broader community and social context of care. Here, in the second of two Series papers on the modern landscape of Ebola disease, we review progress made in the last decade to improve patient-centred care. Although the biosafety imperatives of treating Ebola disease remain, recent advances show how to mitigate these so that patients are cared for in a safe and dignified manner that encourages early treatment-seeking behaviour and provides support after the return of patients to their communities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!